AAVP Strategic Directions and Work Areas

<p>AAVP Strategic Directions and Work Areas</p

The AAVP Structure

<p>GTN, Global Training Network.</p

African Countries Participating in HIV Vaccine Trials

<p>African Countries Participating in HIV Vaccine Trials</p

CD4+ T cell responses and HIV RNA load measurements after MVA85A vaccination.

<p>(A) CD4+ T cell count in 12 HIV+ART−, volunteers (group 1) and (B) in 12 HIV+ART+ volunteers (group 2). (C) HIV RNA load in 12 HIV+ART<b>–</b> volunteers (group 1) and (D) in 12 HIV+ART+ volunteers (group 2). Median values shown in red.</p

IFN-γ secreting cells (ISC) with the summed peptide pools (A, C), the single pool (B, D) per 10⁶ PBMCs for the HIV+ART<b>–</b> and HIV+ART+ groups after the first dose and second dose of MVA85A.

<p>Mann Whitney test was used.</p

Epidemiological and clinical characteristics of HIV-1 eligible volunteers.

<p>Data are median (interquartile range) values when indicated.</p>*<p>ALAT: alanine transferase.</p

IFN-γ secreting cells (ISC) with the sum of peptides (A), the single pool (B) per 10⁶ PBMCs to the HIV+ART<b>–</b> group and HIV+ART+ group at the baseline timeline versus post vaccination.

*<p>Mann Whitney test.</p

Immunogenicity of MVA85A – HIV+ART– group (A, B, C) compared to HIV+ART+ group (D, E, F).

<p>Measured by ex vivo ELISpot assay in the sum of pool of antigen 85A peptides <b>(A, D)</b>, the single pool of 66 peptides antigen 85A <b>(B, E)</b> and in the recombinant antigen 85A <b>(C, F)</b>. The figures also compare the responses after the first (arrow) and second vaccination (arrow).</p

Reasons for exclusion from recruitment into the trial.

*<p>Some subjects were excluded for more than one reason.</p